-
digital.ahrq.gov/sites/default/files/docs/citation/r01hs024538-adelman-final-report-2022.pdf
January 01, 2022 - Understanding the risk of wrong-dose errors in liver transplant
recipients using a validated automated
-
digital.ahrq.gov/sites/default/files/docs/citation/r01hs015274-carayon-final-report-2009.pdf
January 01, 2009 - All CV surgery
patients and acute
MI/post
catheterization;
kidney, pancreas or
liver transplants
-
digital.ahrq.gov/sites/default/files/docs/citation/r01hs020909-dixon-final-report-2017.pdf
January 01, 2017 - only included test results data for a case
of hepatitis B but also corollary results on the patient's liver
-
digital.ahrq.gov/sites/default/files/docs/citation/r21hs023952-chrischilles-final-report-2018.pdf
January 01, 2018 - significant hepatic disease
including cirrhosis, chronic hepatitis B or C, or have current elevated liver
-
digital.ahrq.gov/sites/default/files/docs/publication/uc1hs015339-aranaydo-final-report-2007.pdf
January 01, 2007 - example: a patient with
hepatitis has an automatic diagnosis alert on all meds metabolized by the liver
-
digital.ahrq.gov/sites/default/files/docs/publication/r18hs017099-weiner-final-report-2010.pdf
January 01, 2010 - fatigue, miscellaneous disorders; and a group of more serious diagnoses, which included
categories for liver
-
digital.ahrq.gov/sites/default/files/docs/publication/r18hs017067-kaushal-final-report-2011.pdf
January 01, 2011 - days)
Total cholesterol (6 weeks)
HDL cholesterol (6 weeks)
Thyroid stimulating hormone (6 weeks)
Liver
-
digital.ahrq.gov/sites/default/files/docs/citation/r01hs022955-thompson-final-report-2020.pdf
January 01, 2020 - fundraising;
• Cancer type: Lung, breast, prostate, colon/rectum, ovarian, cervical, kidney, pancreatic, liver
-
digital.ahrq.gov/sites/default/files/docs/citation/r01hs022505-wetterneck-final-report-2020.pdf
January 01, 2020 - information about interactions between
different orders, allergies and adverse reactions, kidney and liver
-
digital.ahrq.gov/sites/default/files/docs/citation/r18hs026170-garcia-final-report-2023.pdf
January 01, 2023 - 3 (2.1%)
Colorectal 2 (5.4%) 10 (7.0%)
Head/neck 0 (0.0%) 3 (2.1%)
Leukemia 0 (0.0%) 15 (10.5%)
Liver
-
digital.ahrq.gov/sites/default/files/docs/publication/u18hs016970-bates-final-report-2012.pdf
January 01, 2012 - to identify ADEs,
medication allergies, comorbidities, specific lab results (e.g., renal function, liver
-
digital.ahrq.gov/sites/default/files/docs/publication/r18hs018646-gance-cleveland-final-report-2014.pdf
January 01, 2014 - Laboratory evaluations covered if a provider requests lipid profile, total cholesterol, glucose, or
liver
-
digital.ahrq.gov/sites/default/files/docs/page/EightSuccessStories_092810.pdf
September 01, 2010 - able to identify a way to sustain itself without public/grant funding.
9 Software designed by the Liver
-
digital.ahrq.gov/sites/default/files/docs/citation/pccds-ln-opioid-action-plan-2019.pdf
January 01, 2019 - This tool displays
treatment options based on comorbid
conditions such severe liver disease,
severe